Antares Pharma (ATRS) Reports In-Line Q2 EPS

Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Incyte acquires Vega Therapeutics for $1.25B upfront
• Buy the pullback in chip stocks, JPM's Matejka says